false 0001138978 0001138978 2023-12-14 2023-12-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest reported): December 14, 2023

 

Novo Integrated Sciences, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   001-40089   59-3691650
(State or other jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification Number)

 

11120 NE 2nd Street, Suite 200, Bellevue, WA 98004

(Address of principal executive offices)

 

(206) 617-9797

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.)

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CF$ 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of Each Exchange on which Registered
Common Stock   NVOS   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On December 14, 2023, Novo Integrated Sciences, Inc. (“Novo”) issued a press release announcing its financial results for the fiscal year ended August 31, 2023. A copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information contained in the website is not a part of this Current Report on Form 8-K.

 

The information furnished pursuant to this Item 2.02, including the information contained in Exhibit 99.1, is “furnished” and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent such other filing specifically incorporates such information by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
     
99.1   Press release issued by the registrant on December 14, 2023.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Novo Integrated Sciences, Inc.
     
Dated: December 14, 2023 By: /s/ Robert Mattacchione
    Robert Mattacchione
    Chief Executive Officer

 

 

 

 

Exhibit 99.1

 

 

Novo Integrated Sciences Reports 2023 Fiscal Year Financial Results

 

BELLEVUE, Wash., December 14, 2023 - Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints providing services and product innovation, today reported its financial results for the fiscal year ended August 31, 2023.

 

Robert Mattacchione, the Company’s CEO and Board Chairman, stated, “The 2023 fiscal year emphasized maximizing efficiencies pointed toward future cost savings and margin stability. The Company remains committed to the commercialization of its proprietary product offerings and the expansion and delivery of its essential services and solutions to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and in the future. Specific to increasing the Company’s cash position, management is primarily focused on raising capital through non-dilutive structures and solutions.”

 

Financial Info for the Fiscal Year Ended August 31, 2023:

 

As of August 31, 2023, the Company’s cash and cash equivalents were $416.3 thousand, total assets were $35.56 million, total liabilities were $11.06 million, and stockholders’ equity was $24.81 million.

 

Revenues for the year ended August 31, 2023 were $12,572,019, representing an increase of $834,082, or 7%, from $11,737,937 for the same period in 2022. The increase in revenue is principally due to an increase in product sales. Acenzia’s and Terragenx’s revenue for the year ended August 31, 2023 was $3,817,346 and $53,751, respectively. Revenue from our healthcare services decreased by 2%, when comparing the revenue for the year ended August 31, 2023 to the same period in 2022.

 

Operating costs for the year ended August 31, 2023 were $13,505,877, representing a decrease of $16,320,038, or 55%, from $29,825,915 for the same period in 2022. The decrease in operating costs is principally due to (i) the decrease in overhead expenses associated with the operations of Acenzia, PRO-DIP, and Terragenx, and (ii) no further impairment of intangible assets and goodwill being recognized in the year ended August 31, 2023.

 

Net loss attributed to Novo Integrated Sciences for the year ended August 31, 2023 was $13,214,552, representing a decrease of $19,634,663, or 60%, from $32,849,215 for the same period in 2022. The decrease in net loss was principally due to (i) a decrease in overhead expenses associated with the operations of Acenzia, PRO-DIP, and Terragenx which was approximately $4,902,925 for the year ended August 31, 2023, (ii) a decrease in interest expenses, and (iii) no further impairment of intangible assets and goodwill being recognized in the year ended August 31, 2023.

 

On December 14, 2021, the Company issued two senior secured convertible notes payable for a total of $16,666,666 (the “$16.66m Notes”), with each note having a face amount of $8,333,333. During the year ended August 31, 2023, the Company made (i) cash payments in the aggregate amount of $3,001,442, principal and interest, and (ii) an aggregate of $8,429,225 in principal and interest was converted into 8,527,835 shares of common stock issued to the $16.66m Note holders.

 

 
 

 

Operational Milestones for the Fiscal Year Ended August 31, 2023:

 

The Company and Farm 7 Group Inc., a Canada corporation (“F7”), entered into a joint venture agreement (the “JV Agreement”) relating to the development, administration, and arrangement of structured financing for the implementation and commencement of the Kenya Agricultural Cooperative Project, a Kenya centric agricultural project with finalized and executed uptake contracts for food-based agricultural goods on up to 9 million hectares with potential revenue up to $350,000,000. The JV Agreement, which has an initial term of 30 years, provides for the annual distribution of the net profits 75% to F7 and 25% to Novo.

 

IoNovo Iodine and IoNovo for Kids Pure Iodine oral sprays granted a registration number and received regulatory approval by Turkey’s Ministry of Health as a dietary supplement determined to be safe, effective, of high quality, and eligible for sale in Turkey.

 

The Company received court approval from the United States District Court for the Central District of California for the Purchase and Sale Agreement which provides for the Company to acquire a certain collection of 43 gemstones, 42 of which are certified by the Gemological Institute of America, known as the “Ophir Collection”, for $60,000,000.

 

The Company entered into a Master Collaboration Agreement with Psychocare Health Pvt. Ltd. India (“PCHPL”), commencing a strategic initiative to introduce new products and state-of-the-art healthcare technologies to the Indian market, with plans to extend healthcare related products to the North American market, providing Novo with access to PCHPL’s over 500 India based franchisee distributors, and providing Novo with an opportunity to integrate into PCHPL’s supply chain. This strategic move is expected to optimize manufacturing processes and enhance market access for Novo brands and products.

 

Corporate Highlights:

 

Subsequent to the fiscal year end, Nasdaq informed the Company that it has regained compliance with the minimum bid price requirement as set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.

 

About Novo Integrated Sciences, Inc.

 

Novo Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation. Novo offers an essential and differentiated solution to deliver, or intend to deliver, these services and products through the integration of medical technology, advanced therapeutics, and rehabilitative science.

 

We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective healthcare distribution.

 

 
 

 

The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers:

 

First Pillar: Service Networks. Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities.

 

Second Pillar: Technology. Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner thus expanding the reach and availability of the Company’s services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral based healthcare services, including the patient’s home.

 

Third Pillar: Products. Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population. The Company’s science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions.

 

Innovation through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting edge advancement in patient first platforms.

 

For more information concerning Novo Integrated Sciences, please visit www.novointegrated.com . For more information on NHL, please visit www.novohealthnet.com

 

Twitter, LinkedIn, Facebook, Instagram, YouTube

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as “believe,” “intend,” “expect,” “anticipate,” “plan,” “potential,” “continue” or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties are discussed in Novo’s filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond Novo’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Novo’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Novo assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The contents of any website referenced in this press release are not incorporated by reference herein.

 

Chris David, COO-President
Novo Integrated Sciences, Inc.
chris.david@novointegrated.com
(888) 512-1195

 

 
 

 

NOVO INTEGRATED SCIENCES, INC.

CONSOLIDATED BALANCE SHEETS

As of August 31, 2023 and 2022

 

   August 31,   August 31, 
   2023   2022 
ASSETS          
Current Assets:          
Cash and cash equivalents  $416,323   $2,178,687 
Accounts receivable, net   1,467,028    1,017,405 
Inventory, net   1,106,983    879,033 
Other receivables   1,051,584    1,085,335 
Prepaid expenses and other current assets   346,171    571,335 
Total current assets   4,388,089    5,731,795 
           
Property and equipment, net   5,390,038    5,800,648 
Intangible assets, net   16,218,539    18,840,619 
Right-of-use assets, net   1,983,898    2,673,934 
Goodwill   7,582,483    7,825,844 
TOTAL ASSETS  $35,563,047   $40,872,840 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
Current Liabilities:          
Accounts payable  $3,513,842   $1,800,268 
Accrued expenses   1,233,549    1,116,125 
Accrued interest (including amounts to related parties)   382,666    454,189 
Government loans and notes payable, current portion   277,405    - 
Convertible notes payable, net of discount of $459,332   558,668    9,099,654 
Contingent liability   61,767    534,595 
Debentures, related parties, current portion   916,824    - 
Due to related parties   533,001    478,897 
Finance lease liability, current portion   11,744    8,890 
Operating lease liability, current portion   415,392    582,088 
Total current liabilities   7,904,858    14,074,706 
           
Debentures, related parties, net of current portion   -    946,250 
Government loans and notes payable, net of current portion   65,038    161,460 
Finance lease liability, net of current portion   -    12,076 
Operating lease liability, net of current portion   1,693,577    2,185,329 
Deferred tax liability   1,400,499    1,445,448 
TOTAL LIABILITIES   11,063,972    18,825,269 
           
Commitments and contingencies   -    - 
           
STOCKHOLDERS’ EQUITY          
Novo Integrated Sciences, Inc.          
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at August 31, 2023 and August 31, 2022, respectively   -    - 
Common stock; $0.001 par value; 499,000,000 shares authorized; 15,759,325 and 3,118,063 shares issued and outstanding at August 31, 2023 and August 31, 2022, respectively   15,760    3,118 
Additional paid-in capital   90,973,316    66,084,887 
Common stock to be issued (91,138 and 414,965 shares at August 31, 2023 and August 31, 2022)   1,217,293    9,474,807 
Other comprehensive (loss) income   (357,383)   560,836 
Accumulated deficit   (67,033,041)   (53,818,489)
Total Novo Integrated Sciences, Inc. stockholders’ equity   24,815,945    22,305,159 
Noncontrolling interest   (316,870)   (257,588)
Total stockholders’ equity   24,499,075    22,047,571 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $35,563,047   $40,872,840 

 

* The consolidated balance sheets’ common stock share amounts have been retroactively adjusted to account for the Company’s 1:10 reverse stock split, effective November 7, 2023.

 

The accompanying footnotes are an integral part of these consolidated financial statements.

 

 
 

 

NOVO INTEGRATED SCIENCES, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

For the Years Ended August 31, 2023 and 2022

 

   Years Ended 
   August 31,   August 31, 
   2023   2022 
         
Revenues  $12,572,019   $11,737,937 
           
Cost of revenues   7,619,304    6,938,699 
           
Gross profit   4,952,715    4,799,238 
           
Operating expenses:          
Selling expenses   15,149    20,702 
General and administrative expenses   13,490,728    14,364,639 
Impairment of assets   -    14,083,531 
Goodwill impairment   -    1,357,043 
Total operating expenses   13,505,877    29,825,915 
           
Loss from operations   (8,553,162)   (25,026,677)
           
Non-operating income (expense)          
Interest income   9,027    169,088 
Interest expense   (360,571)   (1,594,275)
Other income   607,589    - 
Amortization of debt discount   (4,757,121)   (5,973,973)
Foreign currency transaction losses   (215,206)   (641,643)
Total other income (expense)   (4,716,282)   (8,040,803)
           
Loss before income taxes   (13,269,444)   (33,067,480)
           
Income tax expense (recovery)   -    (22,302)
           
Net loss  $(13,269,444)  $(33,045,178)
           
Net loss attributed to noncontrolling interest   (54,892)   (195,963)
           
Net loss attributed to Novo Integrated Sciences, Inc.  $(13,214,552)  $(32,849,215)
           
Comprehensive loss:          
Net loss   (13,269,444)   (33,045,178)
Foreign currency translation loss   (922,609)   (431,605)
Comprehensive loss:  $(14,192,053)  $(33,476,783)
           
Weighted average common shares outstanding - basic and diluted   10,165,548    2,913,263 
           
Net loss per common share - basic and diluted  $(1.30)  $(11.28)

 

* The consolidated statements of operations and comprehensive loss’s share and per share amounts have been retroactively adjusted to account for the Company’s 1:10 reverse stock split, effective November 7, 2023.

 

The accompanying footnotes are an integral part of these consolidated financial statements.

 

 
 

 

NOVO INTEGRATED SCIENCES, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

For the Years Ended August 31, 2023 and 2022

 

   Common Stock  

Additional

Paid-in

   Common Stock To   Other Comprehensive   Accumulated   Total Novo Stockholders’   Noncontrolling     
   Shares   Amount   Capital   Be Issued   Income   Deficit   Equity   Interest   Total Equity 
                                     
Balance, August 31, 2021   2,661,014   $2,661   $54,603,345   $9,236,607   $991,077   $(20,969,274)  $43,864,416   $(60,261)  $43,804,155 
                                              
Common stock for services   75,000    75    1,329,675    -    -    -    1,329,750    -    1,329,750 
Common stock issued as collateral and held in escrow   200,000    200    (200)   -    -    -    -    -    - 
Common stock for conversion of convertible notes   63,653    64    1,272,930    -    -    -    1,272,994    -    1,272,994 
Common stock issued for acquisitions   80,000    80    1,703,920    -    -    -    1,704,000    -    1,704,000 
Common stock to be issued for acquisitions   -    -    -    1,433,475    -    -    1,433,475    -    1,433,475 
Value of warrants issued with convertible notes   -    -    5,553,290    -    -    -    5,553,290    -    5,553,290 
Issuance of common stock to be issued   38,396    38    1,195,237    (1,195,275)   -    -    -    -    - 
Fair value of stock options   -    -    426,690    -    -    -    426,690    -    426,690 
Foreign currency translation loss   -    -    -    -    (430,241)   -    (430,241)   (1,364)   (431,605)
Net loss   -    -    -    -    -    (32,849,215)   (32,849,215)   (195,963)   (33,045,178)
Balance, August 31, 2022   3,118,063   $3,118   $66,084,887   $9,474,807   $560,836   $(53,818,489)  $22,305,159   $(257,588)  $22,047,571 
Units issued for cash, net of offering costs   400,000    400    1,794,600    -    -    -    1,795,000    -    1,795,000 
Cashless exercise of warrants   583,334    583    1,421,000    -    -    -    1,421,583    -    1,421,583 
Share issuance for convertible debt settlement   10,177,834    10,178    9,957,962    -    -    -    9,968,140    -    9,968,140 
Exercise of warrants for cash   532,600    533    532,067    -    -    -    532,600    -    532,600 
Shares issued with convertible notes   265,167    265    247,622    -    -    -    247,887    -    247,887 
Value of warrants issued with convertible notes   -    -    257,994    -    -    -    257,994    -    257,994 
Beneficial conversion feature upon issuance on convertible debt   -    -    164,046    -    -    -    164,046    -    164,046 
Extinguishment of derivative liability due to conversion   -    -    1,390,380    -    -    -    1,390,380    -    1,390,380 
Common stock for services   358,500    359    480,233    -    -    -    480,592    -    480,592 
Issuance of common stock to be issued   323,827    324    8,257,190    (8,257,514)   -    -    -    -    - 
Fair value of stock options   -    -    385,335    -    -    -    385,335    -    385,335 
Foreign currency translation loss   -    -    -    -    (918,219)   -    (918,219)   (4,390)   (922,609)
Net loss   -    -    -    -    -    (13,214,552)   (13,214,552)   (54,892)   (13,269,444)
Balance, August 31, 2023   15,759,325   $15,760   $90,973,316   $1,217,293   $(357,383)  $(67,033,041)  $24,815,945   $(316,870)  $24,499,075 

 

* The consolidated statements of stockholder’s equity share amounts have been retroactively adjusted to account for the Company’s 1:10 reverse stock split, effective November 7, 2023.

 

The accompanying footnotes are an integral part of these consolidated financial statements.

 

 
 

 

NOVO INTEGRATED SCIENCES, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Years Ended August 31, 2023 and 2022

 

   Years Ended 
   August 31,   August 31, 
   2023   2022 
         
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(13,269,444)  $(33,045,178)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   2,302,754    3,019,253 
Fair value of vested stock options   385,335    426,690 
Financing costs for debt extension   1,421,583    - 
Default payment and interest paid through common share issuance   205,349    - 
Common stock issued for services   480,592    1,329,750 
Operating lease expense   797,515    852,580 
Amortization of debt discount   4,757,121    5,973,973 
Foreign currency transaction losses   215,206    641,643 
Impairment of assets   -    14,083,531 
Other receivables write-off   -    299,672 
Goodwill impairment   -    1,357,043 
Changes in operating assets and liabilities:          
Accounts receivable   (597,191)   457,006 
Inventory   (255,781)   (527,397)
Prepaid expenses and other current assets   210,382    (369,647)
Accounts payable   1,770,589    283,234 
Accrued expenses   153,598    38,743 
Accrued interest   (58,066)   101,353 
Operating lease liability   (762,852)   (806,394)
Net cash used in operating activities   (2,243,315)   (5,884,145)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of property and equipment   (49,224)   (190,168)
Cash acquired with acquisition   -    57,489 
Collection of other receivable   -    296,138 
Net cash (used in) provided by investing activities   (49,224)   163,459 
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Receipts from related parties   7,206    16,600 
Proceeds from notes payable   222,780    - 
Repayments of notes payable   (37,130)   (10,591,115)
Repayments of finance leases   (8,611)   (18,435)
Proceeds from issuance of convertible notes   1,285,903    15,270,000 
Repayment of convertible notes   (3,033,888)   (5,104,167)
Proceeds from the sale of common stock, net of offering costs   1,795,000    - 
Proceeds from exercise of warrants   532,600    - 
Net cash provided by (used in) financing activities   763,860    (427,117)
           
Effect of exchange rate changes on cash and cash equivalents   (233,685)   33,328 
           
NET DECREASE IN CASH AND CASH EQUIVALENTS   (1,762,364)   (6,114,475)
           
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR   2,178,687    8,293,162 
           
CASH AND CASH EQUIVALENTS, END OF YEAR  $416,323   $2,178,687 
           
CASH PAID FOR:          
Interest  $432,094   $1,502,819 
Income taxes  $-   $- 
           
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:          
Common stock issued for convertible debt  $9,968,140   $1,272,994 
Common stock issued for acquisition  $-   $1,704,000 
Warrants issued with convertible notes  $257,994   $5,553,290 
Beneficial conversion feature upon issuance of convertible notes  $164,046   $- 
Debt discount recognized on derivative liability  $1,390,380   $- 
Extinguishment of derivative liability due to conversion  $1,390,380   $- 
Debt discount recognized on convertible note  $975,024   $- 
Common stock issued with convertible notes  $247,887   $- 

 

The accompanying footnotes are an integral part of these consolidated financial statements.

 

 

 

v3.23.3
Cover
Dec. 14, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 14, 2023
Entity File Number 001-40089
Entity Registrant Name Novo Integrated Sciences, Inc.
Entity Central Index Key 0001138978
Entity Tax Identification Number 59-3691650
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 11120 NE 2nd Street
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Bellevue
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98004
City Area Code (206)
Local Phone Number 617-9797
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol NVOS
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

Novo Integrated Sciences (NASDAQ:NVOS)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 4월(4) 2024 Novo Integrated Sciences 차트를 더 보려면 여기를 클릭.
Novo Integrated Sciences (NASDAQ:NVOS)
과거 데이터 주식 차트
부터 4월(4) 2023 으로 4월(4) 2024 Novo Integrated Sciences 차트를 더 보려면 여기를 클릭.